Compliance with the faecal calprotectin test in patients with inflammatory bowel disease

Maréchal, Chloé; Aimone-Gastin, I.; Baumann, Cédric; Dirrenberger, Bastien; Guéant, Jean‐Louis; Peyrin–Biroulet, Laurent

doi:10.1177/2050640616686517

Cited by 51 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, CRP determination [4] is limited by poor specificity and sensitivity as (i) CRP level is altered in other acute inflammatory conditions in addition to CD and UC and (ii) up to 25% of patients, who have demonstrable disease activity determined by endoscopy have normal CRP values [5]. FC determination has far greater accuracy for detecting intestinal inflammation than CRP [6] but it requires collection of faecal sample which is cumbersome and has poor patient acceptability [7]. Thus, there is a need for more accurate and non-invasive biomarkers for establishing disease activity in IBD.…”

Section: Introductionmentioning

confidence: 99%

Serum galectins as potential biomarkers of inflammatory bowel diseases

Subramanian

2020

PLoS ONE

View full text Add to dashboard Cite

The inflammatory bowel diseases (IBD), which include mainly Crohn's disease (CD) and ulcerative colitis (UC), are common chronic inflammatory conditions of the digestive system. The diagnosis of IBD relies on the use of a combination of factors including symptoms, endoscopy and levels of serum proteins such as C-reactive protein (CRP) or faecal calprotectin. Currently there is no single reliable biomarker to determine IBD. Galectins are a family of galactoside-binding proteins that are commonly altered in the circulation of disease conditions such as cancer and inflammation. This study investigated serum galectin levels as possible biomarkers in determining IBD and IBD disease activity. Levels of galectins-1, -2, -3, -4, -7 and -8 were analysed in 208 samples from ambulant IBD patients (97 CD, 71 UC) patients and 40 from healthy people. Disease activity was assessed using Harvey-Bradshaw Index for CD and simple clinical colitis activity index for UC. The relationship of each galectin in determining IBD and IBD disease activity were analysed and compared with current IBD biomarker CRP. It was found that serum level of galectin-1 and -3, but not galectins-2, -4, -7 and -8, were significantly higher in IBD patients than in healthy people. At cut-off of 4.1ng/ml, galectin-1 differentiated IBD from healthy controls with 71% sensitivity and 87% specificity. At cut-off of 38.5ng/ml, galectin-3 separated IBD from healthy controls with 53% sensitivity and 87% specificity. None of the galectins however were able to distinguish active disease from remission in UC or CD. Thus, levels of galectins-1 and -3 are significantly elevated in both UC and CD patients compared to healthy people. Although the increased galectin levels are not able to separate active and inactive UC and CD, they may have the potential to be developed as useful biomarkers for IBD diagnosis either alone or in combination with other biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum galectins as potential biomarkers of inflammatory bowel diseases

Subramanian

2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In our experience, we investigated patients' views regarding usability and satisfaction with IBDoc ® . Two thirds of enrolled patients performed the test resulting in double the adherence compared to a previous study of our group showing an adherence rate of 35% with the ELISA test [14]. The test was classified as simple to use by most users (95%) and the percentage of satisfied patients was very high (95%).…”

Section: Discussionmentioning

confidence: 70%

“…Moreover, it has also been applied to some procedures such as the measurement of fecal calprotectin (FC) allowing the home dosage of this biomarker, which is frequently used in daily practice [13]. The FC home measurement does not involve the transport of feces to the laboratory and could improve patient adherence to the test compared to traditional method, which is approximately 40% [14,15]. To date, despite the conceivable benefits associated with the widespread adoption of these innovations, their use in clinical practice is limited and some doubts about their usefulness remain [16].…”

Section: Introductionmentioning

confidence: 99%

Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience

D’Amico

Netter

Baumann

et al. 2020

JCM

View full text Add to dashboard Cite

Technological progress, including virtual clinics, web or smartphone-based applications, and assessment of fecal calprotectin (FC) at home has favored the implementation of treat to target strategies for patients with inflammatory bowel diseases (IBD). Although these innovations are promising and have been associated with a significant reduction in health costs, their application in clinical practice is limited. Here, we summarize the most recent literature on virtual clinics and available FC home tests. In addition, we report the experience of IBD patients monitored through the IBDoc® test at the Nancy University Hospital, focusing on usability testing and patient’s satisfaction. This pilot experience shows that a virtual calprotectin clinic doubles adherence rate to FC in IBD patients. This finding is especially clinically relevant in the post-coronavirus disease 2019 (COVID-19) pandemic era, with an increasing use of e-health.

show abstract

“…Meanwhile, another showed that FC correlated well with the degree of ileal inflammation on cross-sectional imaging and surgical pathology [ 61 ]. However, more recent studies have challenged the efficacy of FC as a surrogate marker for small-bowel CD activity [ 47 , 48 , 62 , 63 , 64 ]. One study found poor correlation between FC and endoscopic disease activity in isolated small-bowel CD [ 47 ].…”

Section: Objective Measurements Of CD Activitymentioning

confidence: 99%

“…Thus, FC cannot be recommended for use in diagnosing or monitoring disease activity in the small intestine, although it remains an excellent biomarker for colonic inflammation in CD. However, stool collection can be burdensome and uncomfortable for many patients, which may lead to poor adherence, as evidenced by a study evaluating FC test compliance in a CD cohort where only 35% (37/101) of participants performed the test [ 64 ].…”

Section: Objective Measurements Of CD Activitymentioning

confidence: 99%

The New Proactive Approach and Precision Medicine in Crohn’s Disease

2020

View full text Add to dashboard Cite

The proactive approach to Crohn’s disease (CD) management advocates moving toward algorithmic tight-control scenarios that are designed for each CD phenotype to guide remission induction, maintenance therapy, active monitoring, and multidisciplinary care to manage the complexities of each inflammatory bowel disease (IBD) patient. This requires accurate initial clinical, laboratory, radiological, endoscopic, and/or tissue diagnosis for proper phenotypic stratification of each CD patient. A substantial proportion of patients in symptomatic remission have been reported to demonstrate evidence of active disease, with elevated fecal calprotectin(FC) and C-reactive protein (CRP) levels as a hallmark for mucosal inflammation. Active mucosal inflammation, and elevated CRP and fecal calprotectin (FC) have been shown to be good predictors of clinical relapse, disease progression, and complications in IBD patients. The next frontier of treatment is personalized medicine or precision medicine to help solve the problem of IBD heterogeneity and variable responses to treatment. Personalized medicine has the potential to increase the efficacy and/or reduce potential adverse effects of treatment for each CD phenotype. However, there is currently an unmet need for better elucidation of the inflammatory biopathways and genetic signatures of each IBD phenotype, so personalized medicine can specifically target the underlying cause of the disease and provide maximal efficacy to each patient.

show abstract

Compliance with the faecal calprotectin test in patients with inflammatory bowel disease

Cited by 51 publications

References 40 publications

Serum galectins as potential biomarkers of inflammatory bowel diseases

Serum galectins as potential biomarkers of inflammatory bowel diseases

Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience

The New Proactive Approach and Precision Medicine in Crohn’s Disease

Contact Info

Product

Resources

About